Oragenics Expands Phase IIa Trial for Concussion Drug with Second Site Activation
Event summary
- Oragenics activates Alfred Hospital as the second site in its Phase IIa trial for ONP-002, a concussion treatment.
- Four patients have already been dosed at the first site, Mackay Base Hospital, since its activation on March 31, 2026.
- The trial aims to enroll 40 patients, with a data readout expected before year-end 2026.
- ONP-002 is the first intranasal neurosteroid designed to reduce neuroinflammation and oxidative stress post-concussion.
- The global concussion market is projected to reach over $9 billion by 2030, with no FDA-approved treatments currently available.
The big picture
Oragenics is advancing ONP-002, a first-in-class intranasal neurosteroid, in a Phase IIa trial for concussion and mild traumatic brain injury (mTBI). The activation of a second trial site underscores the urgent unmet need in this space, with no FDA-approved pharmacological treatments available despite millions of annual cases globally. The company's proprietary intranasal delivery technology positions ONP-002 as a potential paradigm shift from symptom management to active neurological intervention, addressing neuroinflammation and oxidative stress post-injury.
What we're watching
- Trial Execution
- Whether Oragenics can maintain the rapid enrollment pace across both sites to meet the 40-patient target.
- Regulatory Pathway
- The timeline for FDA IND application submission and the potential start of U.S. Phase IIb trials by year-end 2026.
- Market Opportunity
- The pace at which ONP-002 could capture the $9 billion concussion market if approved, given the lack of current treatments.
Related topics